Grace Therapeutics initiated with a Buy at TD Cowen

TD Cowen analyst Stacy Ku initiated coverage of Grace Therapeutics (GRCE) with a Buy rating and $12 price target rating. Based on the Phase III results, TD’s consultants believe that GTx-104 will be a welcome alternative treatment for aneurysmal subarachnoid hemorrhage. Nimodipine is standard of care, and there remains an unmet need for an IV-formulation that optimizes dosing, with the potential for improved tolerability to maximize functional outcomes, the analyst tells investors in a research note.